The sodium salt of γ-hydroxybutyric acid (GHB) is called sodium oxybate. It is a medicine that is used to treat symptoms that are associated with narcolepsy such as abrupt muscle weakness as well as excessive daytime sleepiness. Sodium oxybate is offered under the brand name Xyrem, among other brand names.
In 2002, the Food and Drug Administration (FDA) of the United States gave its approval for the use of sodium oxybate to treat the symptoms of narcolepsy. It was approved by European Union in 2005.
|Name of Product||Sodium Oxybate|
|Synonyms||Sodium 4-hydroxybutyrate; Sodium 4-hydroxybutanoate; Anetamin; Somsanit; 4-Hydroxybutyric acid sodium salt; Gamma OH|
|Molecular Weight||126.09 g/mol|
|3||Solubility||Clear colorless solution at 50mg/ml in water|
|5||IR Spectrum||Consistent with structure|
Although the precise mechanism of action of sodium oxybate for treating extreme daytime sleepiness (EDS) and cataplexy is not understood, it is hypothesized that the drug’s therapeutic actions are related to the GABA(B) effects on noradrenergic, dopaminergic, and thalamocortical neurons.
Some of the side effects associated with the use of Sodium oxybate are-
Potential adverse effects include-
Q. Is sodium oxybate a controlled substance?
Under the Controlled Substances Act, sodium oxybate was placed in Schedule III as a controlled substance for medicinal use when it was used in accordance with an FDA New Drug Application (NDA) or an Investigational New Drug Application (IND), while Schedule I penalties applied to its misuse.
Q. Where to buy Sodium oxybate?